ADA Meeting's Around The Corner: Five Things To Watch For
Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.
You may also be interested in...
In PIONEER 1, weight loss results for the oral version of the GLP-1 agonist were somewhat disappointing and lack of detail in the top-line release prompts concerns about compliance.
Company aims to shift gradually away from once-daily GLP-1 Victoza (liraglutide) toward once-weekly Ozempic (semaglutide).
Biocon’s oral insulin program has received a boost with the US-based JDRF supporting plans to progress its drug candidate in type 1 diabetes. While the pullback of players like Novo Nordisk underscores the potential risks in the oral insulin space, JDRF says early results of Biocon’s candidate “warrant support” for further studies.